PDHA1 Acetylation and Cuproptosis: Mechanistic Insights Into Enzalutamide Resistance in Prostate Cancer

Study Background and Research Question

Castration-resistant prostate cancer (CRPC) is characterized by its relentless progression despite androgen deprivation therapy (ADT), the mainstay treatment for advanced prostate cancer. Resistance to next-generation anti-androgens, such as enzalutamide (Enz), remains a significant clinical barrier, with tumor cells often bypassing androgen receptor (AR) blockade through both AR-dependent and -independent mechanisms. Recent research efforts have focused on uncovering the non-AR pathways that underlie therapeutic resistance, with particular attention to regulated cell death modalities and metabolic vulnerabilities. In this context, the referenced study (Cell Death & Disease (2026) 17:243) interrogates the role of cuproptosis—a copper-dependent form of regulated cell death—within the landscape of CRPC resistance to enzalutamide.

Key Innovation from the Reference Study

The study identifies the pyruvate dehydrogenase E1 alpha subunit (PDHA1) as a pivotal modulator of both cuproptosis and enzalutamide sensitivity in prostate cancer. By delineating a pathway wherein PDHA1-driven acetyl-CoA production enhances histone H3K27 acetylation and transcription of SLC7A11 (a cystine transporter), the authors uncover a metabolic-epigenetic axis that elevates intracellular glutathione (GSH). Elevated GSH, in turn, chelates copper ions and suppresses cuproptosis, thereby attenuating the cytotoxic effects of enzalutamide in resistant CRPC cells. These findings position PDHA1 acetylation signaling as a mechanistic bridge between metabolic reprogramming and therapeutic resistance, suggesting that pharmacological targeting of PDHA1 or its downstream effectors may restore cell death pathways and sensitize tumors to anti-androgen therapy.

Methods and Experimental Design Insights

The research employed a combination of in vitro and in vivo approaches. CRISPR/Cas9 genome-wide screening was utilized to pinpoint key regulators of cuproptosis in CRPC cell lines exposed to copper ionophores and enzalutamide. Knockdown and overexpression experiments clarified the functional role of PDHA1, while metabolic flux analyses quantified acetyl-CoA and GSH levels. Chromatin immunoprecipitation (ChIP) assays examined histone H3K27 acetylation at loci encoding SLC7A11, linking metabolic flux to epigenetic regulation. Further, apoptosis assays and cell viability measurements established the impact of modulating PDHA1 on cell death phenotypes. In vivo, xenograft models in immunodeficient mice assessed tumor growth and response to combined copper and enzalutamide treatment as a function of PDHA1 status.

Protocol Parameters

• PDHA1 modulation: Genetic knockdown (e.g., shRNA or CRISPR/Cas9) or pharmacological inhibition; confirm efficiency via Western blot and enzymatic assays.
• Cuproptosis induction: Copper ionophores (e.g., elesclomol) at concentrations titrated for cell line sensitivity; assess cell death after 24–72 hours.
• Apoptosis assay: Annexin V/PI staining and flow cytometry; Caspase 3/7 activity for confirmation.
• Metabolic flux: Acetyl-CoA and GSH quantification via LC-MS/MS or colorimetric kits.
• ChIP-qPCR: Histone H3K27ac antibody immunoprecipitation; quantitative PCR for SLC7A11 promoter regions.
• In vivo xenograft: Subcutaneous injection of CRPC cells into nude mice; monitor tumor volume bi-weekly; treat with copper ionophore and/or enzalutamide per protocol.

Core Findings and Why They Matter

The central discovery is that PDHA1 activity increases acetyl-CoA, thereby driving histone acetylation and upregulation of SLC7A11. This molecular cascade enhances cysteine import and GSH synthesis, facilitating copper sequestration and suppression of cuproptosis (Cell Death & Disease). As a result, CRPC cells become less susceptible to enzalutamide-induced cell death. Notably, direct inhibition of PDHA1 reverses these effects, restoring cuproptosis and enhancing the anti-tumor efficacy of enzalutamide in both cell-based and animal models. This work highlights a previously underappreciated interplay between mitochondrial metabolism, epigenetic regulation, and therapeutic resistance, underscoring the translational potential of targeting PDHA1 or its downstream pathways in refractory prostate cancer.

Comparison with Existing Internal Articles

These findings complement prior research into mitochondrial metabolism inhibitors for cancer therapy. For example, internal discussions such as “CPI-613: Transforming Tumor Metabolism in Translational Research” and “CPI-613: A Mitochondrial Metabolism Inhibitor for Cancer” have detailed how CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) disrupts mitochondrial energy flux by targeting PDH and KGDH, leading to robust apoptosis in models of acute myeloid leukemia and non-small cell lung carcinoma. Notably, these articles have emphasized the value of apoptosis assays and tumor cell metabolism studies in uncovering vulnerabilities within mitochondrial pathways. The current paper extends this paradigm to prostate cancer, specifically implicating PDHA1 acetylation in the evasion of cuproptosis and resistance to anti-androgen therapy. Furthermore, recent internal work on post-translational modifications of PDHA1—such as succinylation in cholangiocarcinoma (see here)—demonstrates that targeting metabolic-epigenetic intersections is an emerging strategy across tumor types, reinforcing the translational relevance of mitochondrial metabolism inhibition.

Limitations and Transferability

Although the study provides compelling mechanistic evidence, several limitations merit consideration. Most experiments were conducted in established cell lines and immunodeficient mouse models, which may not fully recapitulate the tumor microenvironment of human CRPC. The direct clinical applicability of targeting PDHA1, including potential off-target effects and systemic toxicity, remains to be established. Additionally, while the study focuses on copper-dependent cell death, the broader impact of modulating mitochondrial metabolism on other regulated cell death pathways and immune responses is not fully explored. Nevertheless, the data strongly support further investigation of PDHA1 and metabolic-epigenetic crosstalk as actionable targets in drug-resistant prostate cancer.

Research Support Resources

For researchers seeking to translate these insights into practical workflows, CPI-613 (SKU A4333) provides a well-characterized tool for targeting the pyruvate dehydrogenase complex in cell-based and animal studies. As a selective inhibitor of both PDH and KGDH, CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) enables detailed interrogation of mitochondrial metabolism and cell death mechanisms relevant to apoptosis assay development and tumor cell metabolism studies. For best results, follow manufacturer recommendations regarding solubility and storage, and select workflow parameters that align with the cellular context under study. APExBIO’s CPI-613 is available for research use only and may facilitate the exploration of metabolic vulnerabilities in models of prostate cancer, acute myeloid leukemia, and non-small cell lung carcinoma.